The efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumours of lung or gastrointestinal origin has been demonstrated by researchers. Progression-free survival of patients was successfully extended by seven months and the risk of progression of the disease fell by 52%. Everolimus was well tolerated and side-effects were consistent with the known profile.